Neurocrine Board Authorizes Share Repurchase Program - Quick Facts

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) said its Board has authorized a new share repurchase program under which Neurocrine may repurchase up to $500 million of its shares. The new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.

William Rastetter, Chairman of the Board, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."

For More Such Health News, visit rttnews.com.